Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04622007
Title Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy (KICKSTART)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Effector Therapeutics

lung non-small cell carcinoma



Pembrolizumab + Tomivosertib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST